CISH and melanoma: Delconte et al., 2016 [3] demonstrated the therapeutic benefit of anti-PD-1 and anti-CTLA-4 antibodies in combination with intracellular checkpoint targeting CISH (CISH-deletion) in NK-cells for the treatment of lung metastasis and melanomas in murine model.